Breaking News Instant updates and real-time market news.

VNCE

Vince Holding

$4.71

(0.00%)

, DG

Dollar General

$90.85

(0.00%)

09:16
12/07/17
12/07
09:16
12/07/17
09:16

On The Fly: Pre-market Movers

UP AFTER EARNINGS: Vince Holding (VNCE), up 16.8%... Dollar General (DG), up 5.5%... Ciena (CIEN), up 1.8%... Conn's (CONN), up 7.5%. ALSO HIGHER: Entellus Medical (ENTL), up 49.3% following an announcement that it will be acquired by Stryker (SYK). DOWN AFTER EARNINGS: JinkoSolar (JKS), down 4.2%... Vail Resorts (MTN), down fractionally. ALSO LOWER: Fibrocell Science (FCSC), down 29.6% after its 13.6M share Secondary priced at 77c.

VNCE

Vince Holding

$4.71

(0.00%)

DG

Dollar General

$90.85

(0.00%)

CIEN

Ciena

$21.17

(0.00%)

CONN

Conn's

$31.50

0.05 (0.16%)

ENTL

Entellus Medical

$16.01

-0.25 (-1.54%)

JKS

JinkoSolar

$23.82

(0.00%)

MTN

Vail Resorts

$221.18

(0.00%)

FCSC

Fibrocell Science

$1.01

-0.045 (-4.29%)

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

  • 14

    Dec

VNCE Vince Holding
$4.71

(0.00%)

DG Dollar General
$90.85

(0.00%)

12/04/17
MOFT
12/04/17
INITIATION
MOFT
Neutral
Dollar General initiated with a Neutral at MoffettNathanson
12/04/17
UBSW
12/04/17
NO CHANGE
Target $99
UBSW
Buy
Dollar General price target raised to $99 from $85 at UBS
UBS analyst Michael Lasser raised his price target on Dollar General to $99 from $85 as he views the top and bottom line growth prospects as attractive. The analyst believes margin pressures likely moderated in Q3 and sees the macro backdrop and management initiatives as helping support the company's comps. Lasser reiterated his Buy rating on Dollar General shares.
11/16/17
11/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pandora (P) upgraded to Outperform from Market Perform at BMO Capital with analyst Daniel Salmon saying that despite the lack of near-term catalysts, the market underappreciates longer-term factors. 2. Dollar General (DG) upgraded to Buy from Hold at Deutsche Bank with analyst Paul Trussell saying Dollar General's "long-term profit algorithm" will return in 2018. 3. RH (RH) upgraded to Buy from Neutral at Citi with analyst Geoffrey Small saying the company's initial outlook for 2018 alleviates concerns around the balance sheet and uncertainty regarding demand as the retailer backed off of elevated levels of sales and promotions. 4. Regions Financial (RF) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Ryan Nash saying he sees better than expected net interest margin, improving loan growth and increased capital returns helping Regions reach its efficiency goals in 2018. 5. DSW (DSW) upgraded to Positive from Neutral at Susquehanna with analyst Sam Poser citing momentum in the core women's business and well-controlled inventory levels, which suggest positive inflections are at hand. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/20/17
MKMP
11/20/17
NO CHANGE
Target $96
MKMP
Buy
Dollar General price target raised to $96 from $83 at MKM Partners
MKM Partners analyst Patrick McKeever raised his price target on Dollar General (DG) to $96 and kept his Buy rating ahead of its December 7th earnings, saying both Dollar General and Dollar Tree (DLTR) saw significant comps improvement in the second quarter. McKeever expects more upside going into the holidays as a result of wage gains for the core dollar store customer. The analyst adds that he prefers Dollar General to Dollar Tree due to more attractive valuation as well as his view that its 2.5% SSS forecast may be conservative. McKeever is keeping the latter at Neutral while also raising its price target to $96 from $83.
CIEN Ciena
$21.17

(0.00%)

11/27/17
BOFA
11/27/17
UPGRADE
BOFA
Buy
Ciena upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Tal Liani upgraded Ciena to Buy and maintained a $28 price target saying shares are at the low end of the historical range and the earnings growth profile is attractive.
11/27/17
11/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lowe's (LOW) upgraded to Outperform from Market Perform at Raymond James with analyst Budd Bugatch saying he views Lowe's shares as more attractive following the third quarter beat. 2. T-Mobile (TMUS) upgraded to Buy from Neutral at MoffettNathanson. 3. GlaxoSmithKline (GSK) upgraded to Buy from Neutral at UBS with analyst Michael Leuchten saying concerns of continuing earnings decline and the dividend sustainability are now overdone. 4. Ciena (CIEN) upgraded to Buy from Neutral at BofA/Merrill with analyst Tal Liani saying shares are at the low end of the historical range and the earnings growth profile is attractive. 5. Constellium (CSTM) upgraded to Outperform from Market Perform at Cowen with analyst Novid Russell saying the company's rapid deleveraging has allowed investors to focus on its significant growth projects, attractive end markets, and valuation discount relative to peers. Russell raised his price target to $13 from $11 on Constellium shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/04/17
JEFF
12/04/17
NO CHANGE
Target $32.5
JEFF
Buy
Jefferies likes Ciena's risk/reward heading into 2018
Jefferies analyst George Notter reiterates a Buy rating on Ciena with a $32.50 price target saying he likes for the stock for 2018. The shares are trading "meaningfully below" their historical valuation norms, Notter tells investors in a research note. He sees a "number of avenues" for Ciena to exceed updated views of sales growth for next year, including Verizon's 100G metro project.
11/06/17
GSCO
11/06/17
DOWNGRADE
Target $22
GSCO
Neutral
Finisar downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Doug Clark downgraded Finisar (FNSR) to Neutral and his Telecom Equipment coverage view to Neutral from Attractive citing a more cautious stance on the optical component cycle. The analyst sees softening end markets, rising inventories and industry capacity. For Finisar, which reports earnings in early December, Clark thinks the company's guidance has "significant downside risk" relative to consensus expectations. The analyst cut his price target for the shares to $22 from $27. Finisar closed the trading day down 15c to $19.25. Elsewhere in Telecom Equipment sector, Clark has Buy ratings on Arris (ARRS) and Infinera (INFN), Neutral ratings on Acacia Communications (ACIA), Ciena (CIEN) and Lumentum (LITE), and a Sell rating on Adtran (ADTN).
CONN Conn's
$31.50

0.05 (0.16%)

11/27/17
KEYB
11/27/17
NO CHANGE
KEYB
Rapid erosion in physical stores may be abating, says KeyBanc
KeyBanc's research consumer team says that while online remains the key avenue for growth, the rapid erosion in physical store sales may be abating. The analyst noted that strong store checks reinforce their thesis that apparel is back, with the strongest traffic at Urban Outfitters (URBN) and lululemon (LULU). Meanwhile, Wal-Mart (WMT) was able to eschew wrist bands and had solid inventory of doorbusters, while Gap (GPS) saw strong traffic at Old Navy, they contend. Additionally, KeyBanc's team says its channel checks suggest Best Buy (BBY) continues to gain share and drove healthy traffic, while Bed Bath & Beyond (BBBY) offered slightly more aggressive, but still uninspiring, undifferentiated promotions. Moreover, they believe Conn's (CONN) maintains momentum with its credit offering, credit improvement story, and the recovery in the Hurricane Harvey impacted markets. Checks also revealed solid Beauty positioning, with Ulta Beauty (ULTA) as a winner with strong holiday positioning and good traffic on Thursday/Friday, the analysts added.
10/19/17
RHCO
10/19/17
NO CHANGE
Target $33
RHCO
Buy
Conn's price target raised to $33 from $27 at SunTrust
SunTrust analyst David Magee raised his price target on Conn's to $33 to reflect the impact from expected hurricane rebuilding while also noting the rising charge-offs are only a moderate risk factor. The analyst also expects some improvement in SSS which had fallen about 15% in the first half. Magee maintains his Buy rating on Conn's.
10/18/17
KEYB
10/18/17
NO CHANGE
Target $42
KEYB
Overweight
Conn's price target raised to $42 from $24 at KeyBanc
KeyBanc analyst Bradley Thomas raised his price target for Conn's to $42 from $24 saying it remains a credit turnaround story with building momentum, and that it is evolving into one of recovery in Houston. While the Q3 outlook remains uncertain from the near-term impact of Harvey, the analyst believes investors should look through near-term noise and buy any weakness associated with Harvey. Thomas reiterates an Overweight rating on the shares.
12/07/17
KEYB
12/07/17
NO CHANGE
KEYB
Loss of Conn's a new revenue headwind for Tempur Sealy, says KeyBanc
KeyBanc analyst Bradley Thomas says his channel checks suggest that Conn's (CONN) has dropped Tempur Sealy (TPX) as its exclusive supplier of mattresses, with Serta-Simmons taking its place. The analyst estimates the loss of Conn's could be a 2%-4% drag to Tempur Sealy North America revenue.
ENTL Entellus Medical
$16.01

-0.25 (-1.54%)

12/13/16
PIPR
12/13/16
NO CHANGE
Target $21
PIPR
Overweight
Piper says NICE support of XprESS should help Entellus international growth
After NICE published its recommendation in support of Entellus Medical's XprESS multi-sinus dilation system, Piper Jaffray analyst Matt O'Brien called the news a positive that should help drive adoption outside of the U.S. and support the company's international growth goals. He keeps an Overweight rating and $21 price target on Entellus shares.
05/04/17
ADAM
05/04/17
DOWNGRADE
Target $18
ADAM
Hold
Entellus Medical downgraded to Hold from Buy at Canaccord
Canaccord analyst Kyle Rose downgraded Entellus Medical to Hold from Buy and lowered its price target to $18 from $22 saying the soft Q1 report indicates a slowing in the core US business.
02/22/17
BOFA
02/22/17
DOWNGRADE
BOFA
Underperform
Entellus Medical downgraded to Underperform from Buy at BofA/Merrill
02/22/17
BTIG
02/22/17
DOWNGRADE
BTIG
Neutral
Entellus Medical downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded Entellus Medical to Neutral after the company guided to14%-20% 2017 growth and a larger loss than consensus. "Something has gone off course," the analyst writes in a post-earnings research note. He believes the "business is changing."
JKS JinkoSolar
$23.82

(0.00%)

09/21/17
09/21/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Buckingham. 2. Paycom (PAYC) initiated with an Outperform at Northland. 3. JinkoSolar (JKS) initiated with a Sell at Axiom. 4. Ares Capital (ARCC) initiated with an Outperform at Oppenheimer. 5. Versum Materials (VSM) initiated with a Hold at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/06/17
ROTH
12/06/17
NO CHANGE
ROTH
Tax bill could put 'BEAT' down on U.S. renewables, says Roth Capital
Roth Capital analyst Philip Shen believes the Senate Tax Cuts and Jobs Act includes multiple elements that could negatively affect renewable tax equity capacity, such as a cut in the corporate rate from 35% to 20%, the passage of the Base Erosion Anti-Abuse Tax, or BEAT, without exemptions for solar/wind credits, and a reduction in the number of years the product tax credit could be claimed from 10 down to four years. Near-term, the analyst believes that continued negotiations on the Hill could cause increased volatility for his universe of stocks with direct or indirect exposure to the U.S. solar and wind markets, such as AMSC (AMSC), Broadwind Energy (BWEN), 8point3 Energy (CAFD), Canadian Solar (CSIQ), Daqo New Energy (DQ), Enphase Energy (ENPH), First Solar (FSLR), Hannon Armstrong (HASI), Hanwah Q CELLS (HQCL), JA Solar (JASO), JinkoSolar (JKS), SolarEdge (SEDG), Sky Solar (SKYS), ReneSola (SOL), Sunworks (SUNW), and TPI Composites (TPIC).
09/25/17
ROTH
09/25/17
NO CHANGE
Target $26
ROTH
Neutral
JinkoSolar price target raised to $26 from $18 at Roth Capital
Roth Capital analyst Philip Shen raised his price target for JinkoSolar to $26 from $18 after the section 201 injury vote. However, the analyst notes that the U.S. represents a modest 10%-15% of the company's overall shipments. He reiterates a Neutral rating on the shares.
09/21/17
AXIO
09/21/17
INITIATION
Target $10
AXIO
Sell
JinkoSolar initiated with a Sell at Axiom
Axiom analyst Gordon Johnson started JinkoSolar with a Sell rating and $10 price target. In a research note titled "Earnings "Valentine's Day Massacre" Appears Set to Unfold Imminently," the analyst argues that consensus estimates are ignoring the "sizable risks" to JinkoSolar's earnings in the second half of 2017 and 2018. Johnson sees an "imminent earnings cliff" for legacy PV module vendors with manufacturing origins in China.
MTN Vail Resorts
$221.18

(0.00%)

09/29/17
LEHM
09/29/17
NO CHANGE
Target $247
LEHM
Overweight
Vail Resorts price target raised to $247 from $226 at Barclays
Barclays analyst Felicia Hendrix raised her price target for Vail Resorts to $247 saying the company reported another double-digit increase in season pass sales in Q4. The results show Vail's continued success in signing up new pass-holders and the value to skiers of buying its passes ahead of the season, Hendrix tells investors in a post-earnings research note. She keeps an Overweight rating on the shares.
07/19/17
MACQ
07/19/17
DOWNGRADE
Target $5
MACQ
Neutral
Peak Resorts downgraded to Neutral from Outperform at Macquarie
Macquarie analyst Matthew Brooks downgraded Peak Resorts (SKIS) to Neutral and lowered its price target to $5 due to increased competition from Vail Resorts (MTN) and Aspen/KSL in the Northeast, which could be a headwind to pass sales and valuation. Further, the analyst sees a difficult weather comp in the Northeast that could outweigh the tailwind from an easy comp in the Midwest.
07/21/17
WBLR
07/21/17
INITIATION
WBLR
Outperform
Vail Resorts initiated with an Outperform at William Blair
William Blair analyst Ryan Sundby started Vail Resorts with an Outperform rating.
08/30/17
KEYB
08/30/17
INITIATION
Target $250
KEYB
Overweight
Vail Resorts resumed with an Overweight at KeyBanc
KeyBanc analyst Brett Andress resumed coverage of Vail Resorts with an Overweight rating and $250 price target.
FCSC Fibrocell Science
$1.01

-0.045 (-4.29%)

03/07/17
RODM
03/07/17
INITIATION
Target $2
RODM
Buy
Fibrocell Science initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis started Fibrocell Science with a Buy rating and $2 price target.

TODAY'S FREE FLY STORIES

VNOM

Viper Energy

$38.34

0.91 (2.43%)

21:49
08/16/18
08/16
21:49
08/16/18
21:49
Upgrade
Viper Energy rating change  »

Viper Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIFE

aTyr Pharma

$0.63

(0.00%)

21:45
08/16/18
08/16
21:45
08/16/18
21:45
Upgrade
aTyr Pharma rating change  »

aTyr Pharma upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLT

Hilton

$77.25

1.04 (1.36%)

21:44
08/16/18
08/16
21:44
08/16/18
21:44
Downgrade
Hilton rating change  »

Hilton downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$335.46

-3.2 (-0.94%)

20:50
08/16/18
08/16
20:50
08/16/18
20:50
Periodicals
Tesla Fremont facility workers left 3.5 hours early on Wednesday, BI reports »

Workers at Tesla's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

SPX

S&P 500

$0.00

(0.00%)

, FXI

iShares China Large-Cap ETF

$41.00

0.41 (1.01%)

20:43
08/16/18
08/16
20:43
08/16/18
20:43
Periodicals
Pentagon: China expanded bomber training to overwater areas, Reuters says »

In its annual report, the…

SPX

S&P 500

$0.00

(0.00%)

FXI

iShares China Large-Cap ETF

$41.00

0.41 (1.01%)

BA

Boeing

$345.89

14.16 (4.27%)

HII

Huntington Ingalls

$244.50

3.68 (1.53%)

LMT

Lockheed Martin

$325.86

8.31 (2.62%)

NOC

Northrop Grumman

$291.97

0.45 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$137.38

1.68 (1.24%)

20:25
08/16/18
08/16
20:25
08/16/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

MCD

McDonald's

$161.71

1.82 (1.14%)

19:48
08/16/18
08/16
19:48
08/16/18
19:48
Hot Stocks
FDA updates on investigation of McDonald's salad-related Cyclospora illnesses »

As of August 16, 2018, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

TRP

TransCanada

$43.82

0.05 (0.11%)

19:40
08/16/18
08/16
19:40
08/16/18
19:40
Hot Stocks
TransCanada does not endorse mini-tender by TRC Capital »

TransCanada has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMS

Scientific Games

$30.70

1.4 (4.78%)

, INSE

Inspired Entertainment

$7.15

(0.00%)

19:21
08/16/18
08/16
19:21
08/16/18
19:21
Hot Stocks
Scientific Games and Pennsylvania Lottery launch virtual sports »

Scientific Games (SGMS)…

SGMS

Scientific Games

$30.70

1.4 (4.78%)

INSE

Inspired Entertainment

$7.15

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$15.63

0.23 (1.49%)

19:19
08/16/18
08/16
19:19
08/16/18
19:19
Syndicate
Krystal Biotech announces $10M private placement with Frazier Healthcare »

Krystal Biotech announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

LBC

Luther Burbank

$10.90

-0.09 (-0.82%)

19:08
08/16/18
08/16
19:08
08/16/18
19:08
Hot Stocks
Luther Burbank authorizes stock buyback of up to $15M »

Luther Burbank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

ARAY

Accuray

$3.50

0.05 (1.45%)

, JWN

Nordstrom

$52.30

0.44 (0.85%)

19:00
08/16/18
08/16
19:00
08/16/18
19:00
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

ARAY

Accuray

$3.50

0.05 (1.45%)

JWN

Nordstrom

$52.30

0.44 (0.85%)

CRMT

America's Car-Mart

$66.95

1.85 (2.84%)

ATAI

ATA Inc.

$6.87

0.13 (1.93%)

CORT

Corcept Therapeutics

$12.51

0.01 (0.08%)

VJET

voxeljet

$3.51

0.11 (3.24%)

VNET

21Vianet

$9.45

0.44 (4.88%)

ATGE

Adtalem Global Education

$55.70

-0.3 (-0.54%)

NVDA

Nvidia

$257.57

-1.41 (-0.54%)

AMAT

Applied Materials

$47.42

-0.07 (-0.15%)

MU

Micron

$47.10

-0.38 (-0.80%)

LRCX

Lam Research

$174.22

1.42 (0.82%)

ZOES

Zoe's Kitchen

$9.52

0.04 (0.42%)

VCEL

Vericel

$11.50

-0.075 (-0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

  • 16

    Aug

  • 16

    Aug

  • 16

    Aug

  • 16

    Aug

  • 17

    Aug

  • 17

    Aug

  • 22

    Aug

  • 04

    Sep

  • 05

    Sep

  • 12

    Sep

  • 27

    Sep

  • 06

    Nov

NVEE

NV5 Global

$84.05

1.55 (1.88%)

18:55
08/16/18
08/16
18:55
08/16/18
18:55
Hot Stocks
NV5 Global CEO sells 190,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

  • 20

    Sep

  • 21

    Sep

GOOG

Alphabet

$1,206.00

-7.65 (-0.63%)

, GOOGL

Alphabet Class A

$1,223.55

-8.75 (-0.71%)

18:54
08/16/18
08/16
18:54
08/16/18
18:54
Periodicals
Google submits plans for Moffett Park development, SVBJ reports »

Alphabet's Google…

GOOG

Alphabet

$1,206.00

-7.65 (-0.63%)

GOOGL

Alphabet Class A

$1,223.55

-8.75 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

WMT

Walmart

$98.63

8.39 (9.30%)

18:38
08/16/18
08/16
18:38
08/16/18
18:38
Recommendations
Walmart analyst commentary at Baird »

Walmart price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

AVEO

Aveo Pharmaceuticals

$2.26

0.085 (3.91%)

18:35
08/16/18
08/16
18:35
08/16/18
18:35
Syndicate
Aveo Pharmaceuticals files to sell common stock, no amount given »

Piper Jaffray & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

ZN

Zion Oil & Gas

$2.53

0.16 (6.75%)

18:15
08/16/18
08/16
18:15
08/16/18
18:15
Hot Stocks
Zion Oil & Gas confirms active petroleum system in Megiddo-Jezreel #1 well »

Zion Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRS

Amyris

$7.49

0.07 (0.94%)

18:14
08/16/18
08/16
18:14
08/16/18
18:14
Syndicate
Amyris files to sell 7.4M shares of common stock for holders »

In connection with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CORT

Corcept Therapeutics

$12.51

0.01 (0.08%)

18:07
08/16/18
08/16
18:07
08/16/18
18:07
Hot Stocks
Corcept Therapeutics board member Leonard Baker buys $2.2M in common stock »

Corcept Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Sep

ETSY

Etsy

$45.68

0.83 (1.85%)

17:44
08/16/18
08/16
17:44
08/16/18
17:44
Hot Stocks
Etsy chairman Frederick Wilson sells $1M in common stock »

Etsy chairman Frederick…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

NVDA

Nvidia

$257.57

-1.41 (-0.54%)

, TCEHY

Tencent

$0.00

(0.00%)

17:37
08/16/18
08/16
17:37
08/16/18
17:37
Hot Stocks
Nvidia says 'Fortnite,' 'PUBG' have strengthened video game market »

Nvidia (NVDA) says gaming…

NVDA

Nvidia

$257.57

-1.41 (-0.54%)

TCEHY

Tencent

$0.00

(0.00%)

DIS

Disney

$112.49

-0.42 (-0.37%)

MSFT

Microsoft

$107.65

-0.02 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 04

    Sep

  • 12

    Sep

RCUS

Arcus Biosciences

$12.89

-0.05 (-0.39%)

17:37
08/16/18
08/16
17:37
08/16/18
17:37
Hot Stocks
Arcus Biosciences CEO Terry Rosen buys over 28K shares of company stock »

Arcus Biosciences CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

GLD

SPDR Gold Trust

$111.11

-0.1 (-0.09%)

17:30
08/16/18
08/16
17:30
08/16/18
17:30
Hot Stocks
SPDR Gold Trust holdings fall to 773.41MT from 774.59MT »

This is the 4th…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSTR

L.B. Foster

$23.05

-0.1 (-0.43%)

17:28
08/16/18
08/16
17:28
08/16/18
17:28
Hot Stocks
Breaking Hot Stocks news story on L.B. Foster »

Legion Partners lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HALO

Halozyme

$17.10

-0.1 (-0.58%)

17:25
08/16/18
08/16
17:25
08/16/18
17:25
Hot Stocks
Halozyme director and beneficial owner Randal Kirk sells over 490K shares »

Halozyme director and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.